A first‐in‐human study to evaluate the safety, tolerability and pharmacokinetics of RP3128, an oral calcium release‐activated calcium (CRAC) channel modulator in healthy volunteers-Reference-Cited by-同舟云学术

A first‐in‐human study to evaluate the safety, tolerability and pharmacokinetics of RP3128, an oral calcium release‐activated calcium (CRAC) channel modulator in healthy volunteers

Published:2020-12-11 Issue:3 Volume:46 Page:677-687
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Barde Prajak J.¹^ORCID,Viswanadha Srikant¹,Veeraraghavan Sridhar¹,Vakkalanka Swaroop V.¹,Nair Ajit¹^ORCID

Affiliation:

1. Rhizen Pharmaceuticals SA La Chaux‐de‐Fonds Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13322

Reference19 articles.

1. Ion Channels in Innate and Adaptive Immunity

2. SOCE and cancer: Recent progress and new perspectives

3. Store-operated CRAC channels: function in health and disease

4. Store-operated CRAC channel inhibitors: opportunities and challenges

5. CRAC channels and Ca2+signaling in mast cells

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ORAI1 inhibition as an efficient preclinical therapy for tubular aggregate myopathy and Stormorken syndrome;JCI Insight;2024-03-05

2. Side-by-side comparison of published small molecule inhibitors against thapsigargin-induced store-operated Ca2+ entry in HEK293 cells;PLOS ONE;2024-01-23

3. Immune Cell Ion Channels as Therapeutic Targets;Ion Channels as Targets in Drug Discovery;2024

4. The Ca2+ Sensor STIM in Human Diseases;Biomolecules;2023-08-22

5. Store-operated calcium entry: From physiology to tubular aggregate myopathy;Current Opinion in Pharmacology;2023-02